To assess benefits and harms of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients. To assess separately usefulness for achieving current (or improved) targets in anti-rejection therapy and reducing calcineurin inhibitor side-effects of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients.